Section Editors iiiContributing Authors ivPreface xvPTRIART 1:PLE-NEGATIVE BREAST CANCER1.Epidemiology to Treatment.........................1Triple-Negative Breast Cancer: FromCLIFFORD A. HUDIS2.and Basal Breast Cancers?..........................3What is the Difference between Triple-NegativeMELANIED. SEAL AND STEPHEN K. CHIA3.10,000 Feet..............................................8Triple-Negative Breast Cancers: A View fromMANDIRA RAY AND BLASE N. POLITE4.Triple-Negative and Basal-Like BreastCancer: Promising Clinical Target orOnly a Marker?......................................14Epidermal Growth Factor Receptor inMONIKA L. BURNESS, TATYANA A. GRUSHKO, ANDOLUFUNMILAYO I. OLOPADE5.Antiangiogenic Agents ............................. 24Triple-Negative Breast Cancer: Role ofSALLY GREENBERG AND HOPE S. RUGO6.Tumor Suppression: A Repair-CentricPerspective.............................................30BRCA Gene Structure and Function inCONLETH G. MURPHY ANDMARY ELLEN MOYNAHAN7.Triple-Negative Breast Cancer...................39Poly (ADP-Ribose) Polymerase Inhibitors inELIZABETH A. COMEN AND MARK ROBSON8.Specific Chemotherapy Agents...................44Triple-Negative Breast Cancer: Role ofSTEVEN J. ISAKOFF9.Androgen Receptor ................................. 53Triple-Negative Breast Cancer: Role of theAYCA GUCALP AND TIFFANY A. TRAINAPLOCAL THERAOF LIVER METASTASESART 2:PIES IN THE TREATMENT10.Treatment of Liver Cancer........................57Introduction to Local Therapies in theWILLIAMD. ENSMINGER AND ALFRED E. CHANG11.Hepatic Imaging for Metastatic Disease.......59PETER S. LIU AND ISAAC R. FRANCIS12.Metastasis: Evolving Role in the Setting ofImproving Systemic Therapies and AblativeTreatments in the 21st Century..................69Surgical Treatment of Hepatic ColorectalKAORI ITO, ANANAND GOVINDARAJAN, HIROMICHI ITO,D YUMAN FONG13.Hepatic Malignancies...............................77Thermal Ablative Therapies for SecondarySKYE C. MAYO AND TIMOTHY M. PAWLIK14.Liver Cancer...........................................84Focused Ultrasound as a Local Therapy forKRISZTINA FISCHER, WLADYSLAW GEDROYC, ANDFERENC A. JOLESZ15.Patients with Resectable Liver Metastases....91The Role of Chemotherapy in ManagingTHORVARMICHAEL L. KENDUR R. HALFDANARSON,DRICK, AND AXEL GROTHEY16.via the Operative and PercutaneousTechniques for Patients with Isolated andUnresectable Liver Metastases...................98Development of Isolated Hepatic PerfusionH. RICHARD ALEXANDER, JR., ANDCAROLINE C. BUTLER17.Infusion Pumps.....................................108Implanted Hepatic ArterialMARGARET K. CALLAHAN ANDNANCY E. KEMENY18.Management of Liver Metastases ............. 116Emerging Role of Radiotherapy in theANAND SWAMINATH AND LAURA A. DAWSON19.Metastatic Liver Cancer..........................122Chemoembolization for Primary andELENI LIAPI AND JEAN-FRANCOIS H. GESCHWIND20.for Primary and Metastatic HepaticMalignancies ........................................129Radioembolization (Yttrium-90 Microspheres)ANDREW S. KENNEDY AND RIAD SALEMPCHEMOTHERACANCERART 3:PY FOR COLORECTAL21.Colorectal Cancer..................................143Introduction to Chemotherapy forEDWARD CHU22.Biology of Colorectal Cancer...................144MUHAMMAD WASIF SAIF AND EDWARD CHU23.Advances and Future Directions...............150Stage II and Stage III Colon Cancer: TreatmentBENOˆIT ROUSSEAU, BENOIST CHIBAUJEAN-BACHRISTOTHIERRY ANDEL,PTISTE BACHET, ANNETTE K. LARSEN,PHE TOURNIGAND, CHRISTOPHE LOUVET,DRE´ , AND AIMERY DE GRAMONT24.Gene Profiling in Early Stage Disease ........ 158RACHEL MIHAITHAM AL SALAMA, ANDGLEY, KAKIL RASUL,D DAVID J. KERR25.Chemotherapy for Colon Cancer..............162Optimal Delivery of CytotoxicLAURA RAFTERY AND RICHARD M. GOLDBERG26.Growth Factor Therapies with CytotoxicChemotherapy in the Treatment ofColorectal Cancer..................................168Integration of Anti-Vascular EndothelialSUILANE COELHO RIBEIRO OLIVEIRA,KARIME KALIL MACHAPDO, JORGE SABBAGA, ANDAULO M. HOFF27.Receptor Therapies with CytotoxicChemotherapy......................................174Integration of Anti-Epidermal Growth FactorCE´ SAR SERRANO, BEN MARKMAN, ANDJOSEP TABERNERO28.Colorectal Cancer..................................183Treatment of Liver-Limited MetastaticJOLEEN M. HUBBARD AND STEVEN R. ALBERTS29.with Colorectal Cancer...........................189Chemotherapy for the Elderly PatientDEREK G. POWER AND STUART M. LICHTMAN30.Cancer.................................................201Combined Modality Therapy for RectalBRUCED. MINSKY, CLAUS RO¨ EDEL, ANDVINCENZO VALENTINI31.Metastatic Colorectal Cancer...................210Molecular Markers in the Treatment ofPETER M. WILSON, MELISSA J. LABONTE, ANDHEINZ-JOSEF LENZ32.Metastatic Colorectal Cancer...................221Novel Agents in the Treatment ofSTEAIK CHOON TAN, ANPHEN LEONG, WELLS A. MESSERSMITH,D S. GAIL ECKHARDTPIMMUNOTHERAART 4:PY OF CANCER33.of Cancer.............................................231Introduction for ImmunotherapyJEFFREY S. WEBER34.Chemoimmunotherapy...........................232LEISHA A. EMENS35.Cellular Vaccine Approaches ................... 241DUNG T. LE, DREW M. PARDOLL, ANDELIZABETH M. JAFFEE36.the Next Advance? ................................ 248Immune Regulatory Antibodies: Are TheyJEDD D. WOLCHOK, ARVIN S. YANG, ANDJEFFREY S. WEBER37.Relevant?.............................................255Dendritic Cells: Are They ClinicallyKAROLINAJOSEPALUCKA, HIDEKI UENO, LEE ROBERTS,PH FAY, AND JACQUES BANCHEREAU38.Redirected to the Site of the Tumor?.........262Chemokines: Can Effector Cells BeSTEVEN M.ANDUBINETT, JAY M. LEE, SHERVEN SHARMA,D JAMES J. MUL´E39.to Redirect Effector Cell Specificity...........273Adoptive Cell Therapy: Genetic ModificationRICHARD A. MORGAN, MARK E. DUDLEY, ANDSTEVEN A. ROSENBERG40.Suppression of T-Cell Immunity...............280Regulatory T Cells: OvercomingTATIANA N. GOLOVINA AND ROBERT H. VONDERHEIDE41.in Human Cancer..................................286Myeloid-Derived Suppressor CellsSRINIVAS NAGARAJ AND DMITRY I. GABRILOVICH42.Immune Suppressor?..............................292Indoleamine 2,3-Dioxygenase: Is It anHATEM SOLIMAN, MELANIE MEDIAVILLA-VARELA, ANDSCOTT ANTONIA43.Inhibition and Immunotherapy inMelanoma............................................298Interface of Signal TransductionAMBER L. SHADA, KERRINGTON R. MOLHOEK, ANDCRAIG L. SLINGLUFF, JR.44.T-Cell Clones........................................305Adoptive Therapy Using Antigen-SpecificCASSIAN YEE45.Use in Adoptive Immunotherapy..............312Artificial Antigen-Presenting Cells forCAMERON J. TURTLE AND STANLEY R. RIDDELL46.Good Adjuvants?...................................320Toll-Like Receptor Agonists: Are TheySACHA GNJATIC, NIKHIL B. SAWHNEY, ANDNINA BHARDWAJ47.Candidate Immune Modulators in ImmuneTherapies for Cancer ............................. 330Novel Gamma-Chain Cytokines asNATASHA M. FEWKES AND CRYSTAL L. MACKALL48.Clinical Activity: A Potential Clue to UnlockCancer Immunotherapy..........................337Gene Signature in Melanoma Associated withTHOMAS F. GAJEWSKI, JAMILA LOUAHED, ANDVINCENT G. BRICHARDPTHE ROLE OF THE ONCOLOGIST INART 5:PALLIATIVE CARE49.Palliative Care.......................................343The Role of the Oncologist inNATHAN CHERNY50.Palliative Care.......................................344The Oncologist’s Role in DeliveringNATHAN CHERNY51.Teams Improve Outcomes for CancerPatients and Their Families?....................355What Is the Evidence That Palliative CareIRENE J. HIGGINSON AND CATHERINE J. EVANS52.Oncology Settings..................................367Standards for Palliative Care Delivery inS. YOUSUF ZAFAR,CHRISTODAVID C. CURROW,PHER K. DAUGHERTY, ANDAMYP. ABERNETHY53.Tools in Routine Oncology Practice..........375Utility and Use of Palliative Care ScreeningAMYDP. ABERNETHY, JANE L. WHEELER, ANDAVID C. CURROW54.Realism ............................................... 392Discussing Prognosis: Balancing Hope andTOBY C. CAMBIREN SARAIYA, HOLLY B. YANG, ANTHONY L. BACK,ANPBELL, ELISE C. CAREY, VICKI A. JACKSON,D ROBERT M. ARNOLD55.and When Is It Not?...............................397Palliative Chemotherapy: When Is It Worth ItKEITH M. SWETZ AND THOMAS J. SMITH56.and When Is It Not?...............................403Palliative Radiotherapy: When Is It Worth ItSTELULUEL KHAN, EPHEN LUTZ, TIMOTHY KORYTKO, JANET NGUYEN,DWARD CHOW, AND BENJAMIN CORN57.They Worth It and When Are They Not?...412Invasive Palliative Interventions: When AreFLORIAN STRASSER,DDAVID BLUM, ANDANIEL BUECHE58.Working with a Palliative Care Team........417LAUREN A. WIEBE AND JAMIE H. VON ROENN59.Depression, Anxiety, and Demoralization withAdvanced Cancer .................................. 422The Oncologist’s Role in ManagingSIMON WEIN, AARON SULKES, ANDSALOMON STEMMER60.Advanced Cancer .................................. 429Evidence-Based Approaches to Pain inSYDNEY MORSS DY61.Symptoms in Advanced Cancer................436Evidence-Based Approaches to OtherSYDNEY MORSS AND COLLEEN C. APOSTOL62.Emergencies in Palliative Care..................442DIRK SCHRIJVERS, AND FRANK VAN FRAEYENHOVE63.Treatment Options When ChemotherapyHas Failed............................................449Communication Skills for DiscussingBIREN SARAIYA, ROBERT ARNOLD, ANDJAMES A. TULSKY64.with Advanced Cancer ........................... 452Maintaining the Will to Live of PatientsLULUEL KHAN, REBECCA WONG, MACAMILLA ZIMMERMANN, CHRIS LO, LUCIA GAGLIESE,ANDELINE LI,D GARY RODIN65.Dying Cancer Patient .............................460The Oncologist’s Role in Care of theJUDITH LACEY AND CHRISTINE SANDERSONPIMCANCERART 6:PACT OF HEALTH CARE REFORM ONPATIENTS66.Impact on Childhood Cancer Patients andSurvivors ............................................. 471Health Care Reform 2010: Expected FavorableJULIE WOLFSON, KATHLEEN RUCCIONE, ANDGREGORY H. REAMAN67.Care Act of 2010 on Cancer in Young Adultsin the United States................................479Potential Favorable Impact of the AffordableW. ARCHIE BLEYER68.Act: How Will It Affect Private HealthInsurance for Cancer Patients?.................488The Patient Protection and Affordable CareKARYN SCHWARTZ AND GARY CLAXTON69.Uninsured and Medicaid-Insured CancerPatients................................................492Impact of Health Care Reform Legislation onKATHERINE S. VIRGO, ELIZABETH A. BURKHARVILMA COKKINIDT,DES, AND ELIZABETH M. WARD70.Medicare and Dual Medicare–MedicaidBeneficiaries .........................................499Impact of Health Care Reform onKENNETH E. THORPE AND MEREDITH PHILYAW71.Act: Exploring the Potential Impact onOncology Practice ................................. 503The Patient Protection and Affordable CareJOSEPH S. BAILES, DEBORAH Y. KAMIN, ANDSHELAGH E. FOSTER72.The Intersection of Health Care Reform,Primary Care Providers, andCancer Patients .....................................508An Opportunity for Coordinated Cancer Care:LAUREN G. COLLINS, RICHARD WENDER, ANDMARC ALTSHULER73.Patient: A View from Cancer Executives....514Impact of Healthcare Reform on the CancerLINTERI URSIN GUIDA W. FERRIS, MATTHEW FARBER,DI, AND WILLIAM J. LAFFEY74.of PPACA on Cancer Research.................520The Anticipated and Unintended ConsequencesSTEDPHEN B. EDGE, LEONARD A. ZWELLING, ANDAVID C. HOHN75.Diagnosis Among Patients Aged 55 to 74 Yearsin the National Cancer Database..............527The Association of Insurance and Stage atELIZABETH M. WARVILMA COKKINID, STACEY A. FEDEWA,DES, AND KATHERINE VIRGO76.ObamaCare: Miscalculated Assurances ..... 534ROGER M. BATTISTELLA77.Legislation ........................................... 540Concerns Presented by the New HealthSTUART M. BUTLERIndex 545